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ABSTRACT

Despite of all the research going on for the treatment of ocular diseases, age-related
macular degeneration (AMD) remains one of the serious vision threatening disease worldwide.
Choroidal neovascularization, a pathophysiological characteristic of wet AMD, is the growth of
anomalous blood vessels in the eye choroidal layer. Neovascularization is a key factor in AMD
and thus anti-angiogenic therapy is beneficial in reducing the development of new abnormal blood
vessels to prevent progression of AMD. Axitinib, multi-receptor tyrosine kinase inhibitor, is a
small molecule that works by blocking vascular endothelial growth factor receptors (VEGFR) and
platelet derived growth factor receptors (PDGFR) responsible for developing neovascularization.
Thus, goal of this study was to develop and characterise a sustained release formulation of Axitinib
loaded poly (lactic-co-glycolic) acid (PLGA) nanoparticles. The nanoparticles were
characterized for particle size and zeta potential as well as using DSC, TEM and in vitro drug
release profile. The cytotoxicity of the formulation was evaluated on human retinal pigmented
epithelium ARPE19 cells by MTT assay. The cellular uptake, anti-migration assay, and VEGF
expression levels were found out in vitro using cells. The optimized formulation was 131.33 ±
31.20 nm in size with -4.63± 0.76 mV zeta potential. Entrapment efficiency was found to be 87.9
± 2.7%. The cytotoxicity of ARPE19 cells was less than 12% for nanoparticles suggesting the in
vitro compatibility at 10 µM concentration of drug. Cellular uptake, anti-migration assay and
VEGF expression levels for the nanoparticles had greater uptake, had significant anti-angiogenic
potential and exhibited inhibition of VEGF activity. The results showed successful development
iii

of axitinib loaded PLGA nanoparticles as an alternative potential treatment option for AMD.
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CHAPTER 1: INTRODUCTION

1.1 Introduction

Modern research work in the field of medicine and health focuses on better ways for drug
delivery system to ensure improved therapeutic effects and reduced side effects. Among a lot
research carried out on the biodegradable polymers, polylactic-co-glycolic acid (PLGA) has
proved to be useful as a carrier for drug delivery and tissue engineering (1). PLGA is among the
FDA approved polymers that are efficient as drug delivery vehicle due to their physical stability,
biodegradability and biocompatibility. They have been intensively scrutinized as a vehicle to assist
the delivery of drugs, proteins, nucleotides, and the peptides. The popularity of the PLGA
nano/micro particles is also due to its ability to enhance a sustained drug delivery process,
favourable deterioration abilities and the experience in the clinical field (2). Again, through control
of various parameters, the physical properties of a polymer-drug complex can be adjusted to suit
the appropriate dosage and release interval considering the type of the drug being dealt with.
However, the toxicity associated with these require a critical analysis to enhance safety (3).
Polylactic-co-glycolic acid is a copolymer of two compounds; the polylactic acid (PLA) and the
polyglycolic acid (PGA). Also, the mixture contains an asymmetric α-carbon which can be
described either in D and L or R and S forms. The enantiomeric forms of the compound also exist,
and in general, PLGA is an acronym for the D, L- lactic-co-glycolic acid in which the D and L
forms of the lactic acid live in equal proportions (4).
1

Axitinib is a tyrosine kinase inhibitor and works by blocking the vascular endothelial
growth factor receptors (VEGFR) which in turn inhibit the activity of the endothelial growth
factors. Also, it plays a crucial function in inhibiting the function of platelet-derived growth factor
receptors (PDGFR) thus leading to the inhibition of neovascularization development (5).
Therefore, administering axitinib intravitreally has proved to be useful in managing wet agerelated macular degeneration therapy which reduces neovascularization and macular thickness
thus containing the damage because of the age-related macular degeneration (6).
Age-related macular degeneration (AMD), one of the major cause for loss of vision affects
many elderly patients worldwide (7). Among two types of AMD, wet-AMD is one foremost cause
of vision loss and is linked to choroidal neovascularization. The acellular debris accumulates
which leads to damage to macular site in retinal epithelium results into blurring of the vision (8).
In response to damage in the epithelial layer, vascular endothelial growth factors (VEGF) secretion
begins. Additionally due to dysfunction of ion channel and abnormal metabolism of lipid oxidative
damage to cells take place (9). To pay damages for the reduce blood supply at the site, new
blood vessel will start to form which will in turn increase inflammation (10, 11). Angiogenesis is
an essential phenomenon of formation of new vessels in the vasculature and one of their
important regulators are tyrosine kinases (12). Anti-VEGF therapy has become well known to
reduce angiogenesis in cancer. Even for treatment of wet-AMD anti-VEGF therapy has gained a
lot of interest to reduce neovascularization for treatment of AMD. Current therapy for AMD
involves intravitreal administration of antiangiogenic agents such as Lucentis™ (Ranibizumab),
Macugen® (Pegaptanib), Avastin® (Bevacizumab). However, there is rapid clearance of these
agents from site of action requires frequent intravitreal instillations which increase the risk of as
detachment of retina, endophthalmitis, infections, vitreous haemorrhage and increased
2

intraocular pressure (13) as well as reduces patient compliance. Thus, there is requirement of
such delivery system which can minimize intravitreal instillation frequency of anti-angiogenic
agents for efficient therapy of AMD. In the present research, axitinib loaded PLGA nanoparticles
(AX-NPs) were developed and evaluated for size, zeta potential, surface morphology and in vitro
drug release along with its in vitro cellular uptake and cytotoxicity. Its anti-angiogenic potential
to inhibit cell migration and VEGF expression was also studies in vitro.
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CHAPTER 2: MATERIALS AND METHODS

2.1

Materials

Axitinib was bought from the Selleck Chemicals, Houston, TX, USA. Poly (DL-lactideco-glycolide) (PLGA, Mw 15000 Da) containing lactide/glycolide ratio of 50:50 was acquired
from the Acros Organics (NJ, USA). Polyvinyl alcohol, Mw 100000, was purchased from the
Fisher Scientific (USA). Both the Coumarin 6 dye and the Dialysis membrane, Mw 10000, was
outsourced from Sigma Aldrich (St. Louis, MO). Fetal Bovine Serum and penicillin-streptomycin
(10000 U/ml) were purchased from Gibco Thermo Fisher Scientific, USA. 3-(4,5-dimethylthiazol2-yr)-2,5-diphenyltetrazolium bromide salt (MTT reagent), and nucleus stain DAPI (4′,6diamidino-2-phenylindole) both of which were outsourced from the Tocris Bioscience (MN,
USA). Cell maskTM deep red plasma stain was obtained from Thermo Fisher Scientific, (USA).
BCA protein assay kit and Invitrogen™ eBioscience™. Human VEGF-A Platinum ELISA Kit
were purchased from Fisher scientific branch in USA. ARPE-19, a human retinal pigment
epithelial cell line (ATCC® CRL2302™) and Dulbecco’s Modification of Eagle’s Medium F 12
(DMEM F12) was obtained from American Type Culture Collection (ATCC) (VA, USA). Cell
culture Phosphate Buffer Saline (1X) (PBS) was obtained from Corning Cellgro (Manassas, VA).
Trypsin (0.05%) was purchased from Thermo Fisher (Lansing, MI). All the analytical reagent used
were analytical grade and hence no further purification was needed.
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2.2

Cell Culture

All the cell line studies were performed on the human retinal epithelial cell line, ARPE-19
(ATCC CRL2302™). DMEM F12 medium supplemented with 10% v/v FBS and 1% 10000 u/ml
penicillin-streptomycin antibiotics were used for the maintenance of cells. The cells were
incubated in a humidified atmosphere at 5% CO 2 at 37 °C.

2.3

Preparation of Axitinib Loaded PLGA NPs

AX-NPs were prepared by the o/w solvent evaporation method (2). The drug and the
polymer were dissolved in a 2 ml of DMSO: acetone (1:9 vol/vol) at a weight ratio of 1:7 at room
temperature. The resultant solution was then slowly added into 1% w/v PVA solution using 23G
syringe while in constant stirring at 700 rpm at room temperature (RT). After that, the organic
solvent was allowed to evaporate at RT, and the resulting volume of the aqueous dispersion was
collected. The suspension was then centrifuged at 5000 rpm for 5 mins at RT so that the
unentrapped drug can be removed. Further the supernatant was centrifuged at 18000 rpm at 4 ºC
for about 2 h to allow nanoparticles to settle down. After being centrifuged, pelleted nanoparticles
were washed using distilled water and collected (2). In the same manner, blank nanoparticles
excluding the drug and Coumarin 6 loaded nanoparticles were formulated. Figure 1 shows the
graphical presentation of the preparation method of AX-NPs.

5

Figure 1: (A) Structure of PLGA with its monomers, (B) Structure of the axitinib drug, (C)
Graphical representation of method of preparation of AX-NPs.
2.4

Differential Scanning Calorimetry

The analyses of the sample using the differential scanning calorimetry were conducted on
the DSC- Q 20 (TA Instruments, New Castle, DE USA, Q series Q20-2288-DSC software).
Blank aluminium pan was used as a reference (14). About 4mg of the sample powders were then
heated form a temperature of about 30 to 300 ºC at a rate of 10°C min -1 under the nitrogen purge
(50 mL/min) (15). The procedure was carried out in both the thermal analysis involving pure
axitinib drug, the physical mixture of axitinib and the PLGA nanoparticles, polymer and lastly on
6

the axitinib loaded PLGA nanoparticles.

2.5

Particle Size and The Zeta Potential

Through the aid of a laser dynamic light scattering (DLS), the mean particle sizes of AXNPs were determined. This investigation was carried out within a measuring angle of about 90 º at
a temperature of approximately 25 ºC using a sample, adequately diluted with filtered distilled
water (16). For every sample analysed, the mean diameter and the standard deviation of five
readings were determined through the application of the multimodal analysis. The outcome of the
analysis was then reported in triplicates. The results of zeta potential were obtained along with
polydispersity index (PDI).
Zeta potential of nanoparticles was determined based on Smoluchowski equation that
considers electrophoretic mobility of the nanoparticles and their back-scatter at 90° (17). The
analysis was carried out in triplicate after ten times dilution of nanoparticles using double distilled
water using zeta cuvette and Zeta Sizer Nano ZS 90 (Malvern Instruments Ltd., UK, Zeta Sizer
Software Ver. 7.10)

2.6

Transmission Electron Microscopy

Transmission Electrode Microscope (TEM) (JEOL JEM 1400 electron microscope with
Gaton camera, Peabody, MA, USA), was used to study the morphology, size and shape of AXNPs. This involved placing the sample on the EMS formvar support film square grid, 200 Cu. It
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was then allowed to air dry approximately for 5 to 10 minutes. It was further treated with 2% w/v
phosphotungstic acid for negative staining. The investigation was conducted at an accelerating
voltage of about 120 kV with 40000 magnifications.

2.7

Entrapment Efficiency

AX-NPs were first centrifuged at 5000 rpm for 10 mins to remove the unentrapped drug
from the suspension. Then the collected supernatant containing NPs was further centrifuged at
18000 rpm for 20 min to collect AX-NPs pellet. The pellet was washed thrice with DI water to
separate the traces of unentrapped drug from the surface and collected. Analysis was done using
UV spectrophotometer at a wavelength of 260 nm (λmax) in methanol as a solvent. The contents
of the AX drug were then determined from the UV curve produced. Hence the AX entrapment
efficiency and the loading efficiency were calculated through using below equations.

% Entrapment efficiency = Actual amount of drug loaded in nanoparticles ×100
Actual amount of drug used for preparation
% Loading efficiency = Amount of AX in nanoparticles ×100
Total amount of nanoparticles
2.8

In Vitro Drug Release Study

The in vitro drug release study of axitinib solution in DMSO and AX-NPs was carried out
using dialysis bag (MWCO 10000 Da) diffusion technique (18). The dialysis tube was immersed
in 20 ml of release medium (Phosphate buffer saline with pH 7.4) containing 0.1% (v/v) Tween
8

80. Using a magnetic stirrer, the contents were continuously stirred at 150 rpm and the temperature
was adjusted to 37 ⁰C. At predetermined intervals of 0.25, 0.5, 1, 2, 3, 4, 5, 6, 12, 24, 48, 72, 96,
120, 144 and 168 hrs., 1 ml of sample was removed and replaced with the fresh release media.
Drug concentration was determined by using the UV spectrophotometry at a wavelength of 260
nm after dilution of the sample with methanol.

2.9

Cytotoxicity Study

The MTT assay was initiated to help determine the level of cytotoxicity associated with
the AX-NPs comparing it with the pure drug solution, in ARPE-19 cell line (human retinal pigment
epithelial cells). The cells were cultured at a suitable density of 5000 cells/well in a 96 well plate
in 200 μl of DMEM supplemented with 10% FBS. The incubation was carried out at a temperature
of about 37 °C with access to 5% atmosphere CO2 for 24 h to enable proper attachment and
assist in the growth of the cells (19). Both the formulations involving the nanoparticles and the
pure drug solution were subjected to dilution using as serum-free DMEM F12 medium to come
up with varied concentrations of axitinib drug. After 24 h culture, the cells were treated with
prepared formulations and the treatment was kept for 4 hours. At the end of the incubation
period, the treatment was removed, and cells were washed once using sterile 1X PBS. The
procedure was then followed by the addition of fresh complete DMEM F12 medium containing
10% FBS for period of 24 to 48 h. After specified time, 100 μl of MTT reagent (1 mg/mL)
solution was added to each well and the cells were incubated in same condition as previous for 4
h (17). The medium in each plate was then replaced with 100 μl of dimethyl-sulfoxide and
intensity of the colour of the dissolved formazan crystals was measured using microtiter plate
9

reader at wavelength 595 nm. Cells treated with DMEM F12 acted as the negative control while
the ones treated with 0.1% Triton X were the positive control in the experiment. Cell viability was
given relative to that of the negative control (20)

2.10

Cellular Uptake

To determine the cell uptake potential of the AX-NPs, confocal microscopy was carried
out. Prepared formulations like blank nano-formulation, drug formulation and coumarin
formulations were prepared. The cells were seeded in the density of 2x10 5 per well in a six well
plate. The plate in the incubated to achieve 70% confluency. The cells was washed thrice with
PBS. The wells were then treated with the prepared coumarin loaded nanoparticles and blank
nanoparticle as a reference. The six well plate was then incubated with all the prepared nanoformulations for the period of 4 hrs. The plate is then subsequently washed thrice with PBS and
then fixed with 4% paraformaldehyde. DAPI was used as a nuclear staining followed by Cell-mask
™ deep red staining for membrane staining. This is then examined under confocal microscope
FV1200 (Olympus, Tokyo, Japan) at 60x magnification.

2.11

Wound Scratch Assay

Wound healing assay procedure was carried out to assist in the analysis of the inhibitory
effect of axitinib and its formulation on VEGF induced angiogenesis. Human retinal pigment
epithelial cells were grown in twenty-four well plates and allowed to reach 80% confluency. The
wounds were then developed with much care using pipette tip. The average size of the wounds
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developed was measured and found to be around 300μm. for the sake of the study, wound width
within 5% variation was considered. The wounds were then cleaned with sterile PBS two times
eliminate partly adhered cells on the plates due to the wound. These wells were then subjected to
treatment using the serial dilution of drug formulation and Nanoparticulate formulation in
incomplete media at 1µM and 10µM concentration (21).
Cell migration was analysed under the microscope and quantified through obtaining the
measurements of the area covered by the cells that had migrated from the wound edges using
Image software. To inspect the effect VEGF on the cell migration, two wells were also kept at high
two concentrations and treated with VEGF simultaneously. Thus, one well consisted of a complete
medium while the other one was treated with VEFG to act as reference and controls in that order.
Incubation was done still at the average body temperature of about 37 °C in a CO2 incubator (5%)
for 48 hrs. The treatments were removed after incubation, and the cells were washed with PBS
three times, fixed using 70% ethanol. Images were then obtained, and the wound width was
measured using images captured by the microscope. The width of the untreated group at 0 h was
considered 100% and relatively % recovery of the wound was compared.

2.12

Anti-VEGF ELISA

Human retinal pigment epithelial cells were cultured in twenty-four well plates at the
density of 5 x 104 cells/mL and allowed to become confluent. The day of the examination, the
culture media was replaced with incomplete media and subjected to treatment. The treatment group
consisted of a free drug solution and axitinib-NPs, each at 10µM concentration and were further
incubated for a total period of 72 hours (22). Quantification of the secreted VEGF in the culture
11

media was done by ELISA method using Human VEGF-A Platinum ELISA Kit following
manufacturer’s instructions. The protein content in the cells was estimated using Pierce BCA
protein assay kit after collecting cell lysate and the by normalizing VEGF secretion to total protein.
Samples were read using ELISA plate reader at 450 nm absorbance, and 550 nm and the difference
were recorded, followed by calculating inhibition of VEGF secretion using standard curve.

2.13

Statistical Analysis

The results obtained were presented as mean and the standard deviation and the
investigation conducted with the aid of students t-test. The variance in the lipid profile was
investigated statistically using a one-way analysis of variance followed by turkey’s test. The
probability values od p˂0.05 were statistically significant.
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CHAPTER 3: RESULTS AND DISCUSSIONS

3.1

Differential Scanning Calorimetry

Pure AX drug, physical mixture of PLGA and AX as well as AX-NPs were studied for
physicochemical characterization using differential scanning calorimetry (DSC) technique. Figure
2 demonstrates DSC thermal analysis of AX, physical mixture of AX and PLGA and AX-NPs
(15), (13), (27). The physical state of drug molecule in NPs affects their release and solubility in
external medium and so DSC thermograms is helpful in identifying the nature or physical state of
drug alone and while being loaded in NPs (28). AX showed sharp endothermic peak at around 212
⁰C indicating its specific melting point.

Figure 2: DSC spectra of (A) AX pure drug, (B) AX-NPs formulation and (C) AX and
PLGA physical mixture.
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This endothermic peak was not present in DSC spectra of AX-NPs approving the complete
loading of AX in NPs and confirming amorphous form of loaded AX. Incompatibility between the
polymer and drug can also be determined from DSC thermograms from the alterations in the
transition temperature of individual components that generates added peaks in thermogram (23).
Thus, DSC study also disclosed the compatibility of the AX and PLGA.

3.2

Particle Size and Zeta Potential

The size of AX-NPs was measured using DLS technique and was found to be 131.33 ±
31.20 nm with PDI of 0.108 ± 0.005. The mean zeta potential of AX-NPs was determined using a
Malvern Zetasizer Nano ZS90 and was found to be -4.63± 0.76 mV. Figure 3(A) shows Z-average
for the particle size for AX-NPs (24). It has been observed that with increased concentration of
PLGA at drug to PLGA weight ratio of 1:10, the axitinib entrapment was not increased
significantly however an increase in the PLGA concentration resulted in increased viscosity of the
organic phase thus the diffusional resistance of drug particles from the organic phases to the
aqueous phase was increased. This led to increase in the particle sizes of particles (data not shown).
Thus, 1:7 weight ratio was optimised for preparation of AX-NPs. The zeta potential affects the
stability of the nanoparticles both extremes significantly either in the positive side or the negative
side leads to higher repulsive forces being witnessed. The repulsive forces existing between similar
electric charge blocks and hence they enhance the ease of dispersion. For the combined dynamic
and steric stabilization, minimum zeta potential is recommended. Formulation involving the use
of non-ionic surfactants exhibited average zeta potential whereas the formulations without the use
of surfactant demonstrated a higher zeta potential. This scenario depicted could be due to the
14

existence of carbonyl groups within the extremes of the polymeric chains of pure PLGA
nanoparticles (25).

3.3

Transmission Electron Microscopy

TEM revealed that the particle size of AX-NPs was around 110 nm. Though this was in
disagreement with that of particle size obtained by dynamic light scattering, such difference can
be easily realized as DLS reports the hydrodynamic diameter of the particles whereas in TEM
analysis the size obtained was of the particle fixed in grid. TEM images (figure 3 (B)) confirmed
nanoparticles of uniform size and were in concurrence with the DLS results and were spherical
with smooth surface. TEM was used to confirm the information that the nanoparticles were
spherical and was not in aggregate.

Figure 3: A. Z-average of AX-NPs, B. TEM image of AX-NPs with 40,000X magnification
at accelerating voltage of 120 kV (scale bar 0.5 µM).
3.4

Entrapment Efficiency

Encapsulation efficiency was calculated by centrifuging the NP solution and
resuspending the NP pellet in methanol. Entrapment efficiency was found 87.9 ± 2.7%. Percent
15

drug loading was found to be around 11%. UV spectroscopy was used to determine the
encapsulation efficiency of AX by comparing the absorbance in methanol to standard dilutions
of AX in methanol (r2=0.9994) at λmax of 260 nm. Three weight ratios (1:5, 1:7, 1:10) of
AX:PLGA were studied to see the effect of polymer concentration on entrapment and loading of
the drug in NPs. Out of which 1:7 was optimised as significant increase in entrapment efficiency
was observed compared to weight ratio of 1:5. However there was no significant change in
entrapment efficiency was observed for weight ratio of 1:10 (optimization data not shown).

3.5

In Vitro Drug Release Study

The in-vitro release study of AX from drug solution and AX-NPs were carried out by
dialysis method. To mimic the in vivo eye posterior area environment, phosphate buffer saline
having pH of 7.4 was used a release media and the study was performed at 37 °C. Tween-80 (0.1%
v/v) was added to the release medium to improve the solubility of drug in release medium as well
as to maintain the sink condition. The release profile of AX from solution as well as NPs have
been shown in figure 4 for the period of 7 days.

Figure 4: Cumulative drug release of AX from AX solution and AX-NPs up to 7 days at 37
°C in phosphate buffer saline at pH 7.4, (mean ± SD, n =3).
16

The release of AX from solution was rapid and almost 100% of AX was released within 6
h in release medium. While the AX-NPs initially demonstrated burst release of 18.4±2.2 % of
AX within first hour which may be because of the adhered drug to the outer surface of NPs. But,
after that AX-NPs exhibited sustained release profile ox AX with 23.7±1.4% release at the end of
24 h followed by 84.2±4.1% at the end of seven days (26).

3.6

Cytotoxicity Study

The cytotoxicity of the AX drug solution and AX-NPs was studied using the MTT assay
in the human retinal pigmented epithelium cell line ARPE-19.

Figure 5: % cell viability at different concentrations of AX drug solution and AX-NPs at
(A) 24 h and (B) 48 h in ARPE 19 cell line, (mean ± SD, n =3).
17

Cells were treated in serum-free medium with various concentrations (0.001, 0.01, 0.1, 1,
10 and 20 μM) of AX in solution as well as NPs in triplicates for 24 and 48 h. To study the
cytotoxic potential of polymer alone, blank PLGA NPs were also evaluated for MTT assay. The
resulting cell viability was compared to that of the control untreated cells, which was established
as 100%. Results specified that the viability of cells was higher than 90% for AX-NPs at 10 µM
and 20 µM concentration tested for both the time points tested whereas, for drug solution
viability at 20 µM was found to be 78% and 63% respectively for 24 h and 48 h, thus
demonstrating non-toxic nature of NPs (figure 5). The biocompatible and biodegradable nature
of PLGA has been demonstrated so far and thus FDA has approved use of PLGA based on its
safety profile. Data from MTT assay also supported its biocompatible nature with ARPE-19
cells.

3.7

Cellular Uptake

Coumarin-6 loaded PLGA NPs were evaluated for cellular uptake upon incubation with
ARPE-19 cells at 37 °C. Coumarin-6 is a hydrophobic fluorescent dye which mimics
hydrophobic nature of AX and was used to locate the nanoparticles and their uptake in to the
cells. Figure 6 shows confocal images demonstration the uptake of coumarin 6-loaded PLGA
NPs into ARPE 19 cells at various time points at 37 °C. The left first panel shows nucleus
stained with nucleus staining dye DAPI with blue fluorescence. The next panel is representing
presence of cells as red fluorescence is because of the stained cell membrane with Cell Mask
Deep Red stain. In the third panel from the left, uptake of coumarin-6 loaded NPs was observed
and showing green fluorescence in the cytoplasm of the cells which confirms presence of NPs in
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cell cytoplasm and the last panel demonstrating the merged images of all. The blank in the figure
is untreated cells which were kept as control. The intensity of green fluorescence depicting
uptake of NPs in cells has been observed to increase with increase in treatment time. This may be
because of the fact that the uptakeof NPs follows receptor mediated endocytosis process and with
increase in the treatment time more NPs can bind with the VEGFR present on the ARPE-19 cells
leads to enhanced cellular uptake.

Figure 6: Cellular uptake of coumarin 6-loaded PLGA NPs in ARPE-19 cells at various
time points at 37 °C.
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3.8

Wound Scratch Assay

Wound scratch assay was performed to study migration of the cell which is one of the
primary stages that leads to angiogenesis. The evaluation of the cell locomotion avails a significant
estimation of inhibition of cell growth through conducting appropriate measurement on wound
recovery under microscopic evaluation (27).
The cells were imaged immediately after making a wound served as a reference while the
untreated group demonstrating covering of wound naturally served as a control. Figure 7(A)
demonstrates microscopic images showing recovery of wound after treatment of cells with AX
solution and AX-NPs in presence and absence of angiogenesis promoting agent (100 nM of
VEGF165, rhVEGF; R&D Systems). Fig. 7 (B) shows the % wound recovery for respective
images in quantifying graphical plot. Concentration dependent inhibition of wound recovery was
observed (p < 0.01); least for the group with maximum concentration of AX in NPs (10 µM). The
100 nM of VEGF165 (rhVEGF; R&D Systems) increased the migration of cells to greatest extent
and hence wound recovery as seen in fig. 7 (A). However, co-treatment of AX-NPs formulation
with VEGF165 could resist the action of VEGF165 as well as inhibited VEGF-induced angiogenic
manifestations in ARPE-19 cells and did not significantly improved the cell migration based
wound recovery. These results indicate that AX-NPs efficiently and selectively inhibits VEGFinduced angiogenesis in ARPE-19 cells.
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Figure 7: (A) Wound scratch assay images for ARPE-19 cells treated pure AX drug
solution (AXD), various concentration of AX-NPs (AXF) in presence and absence of VEGF
165. (B) Percent wound covered after 48 h in comparison to control for AXD and AXF at
various concentrations in presence and absence of VEGF 165, *P < 0.01 vs control, (mean ±
SD, n=3).
21

3.9

Anti-VEGF ELISA

The effect of the AX drug solution and AX-NPs on secretion of VEGF was studied using
Anti-VEGF ELISA in ARPE-19 cells. Samples were collected after 12, 24, 48 and 72 hours of
treatment and the amount of VEGF-A was measured using the Human VEGF-A Elisa kit. %
VEGF secretion values are demonstrated using the control group value as 100% (Figure 8).
VEGF secretion was noticeably reduced by the free AX solution throughout all treatment groups.
AX-NPs have similar effects on VEGF-A secretion. ELISA results showed significantly (P <
0.05) decreased VEGF protein levels after exposure to AX-NPs (10 µM equivalent of AX) in
ARPE19 at 24, 48, and 72 h in comparison with control cells and cells treated with drug solution.

Figure 8: % VEGF expression in ARPE-19 cells treated with AX drug solution and AXNPs for different time point determined using ELISA assay method (mean ± SD, n =3).
The observation depicted could be because of an initial high level of free drug available
within the cells in case of employment of the solution form of the medicine since the correlation
of the scenario with the release profile of the formulation is hard to be determined. However, in
case of nanoparticle formulation, there was an initial low level of VEGF control which at later
time points became stronger as the drug released from the matrix over a longer duration (28), (29).
22

Therefore, an end to note is the excellent sustained inhibitory effect of nanoparticle formulation as
compared to drug solution was observed.
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CHAPTER 4: CONCLUSION
The AX-NPs was successfully developed, characterized and tested in vitro in human retinal
epithelial ARPE-19 cells manifesting its effectiveness in the wet AMD. The formulation may
present an important approach of treating wet-AMD due to its capability in ensuring a sustained
release of drug and potential in inhibiting VEGF expression which in the clinical field is of great
importance. It is therefore considered more superior as compared other oral formulations that
portray low efficacy with more side effects. The intravitreal installation of the prepared
nanoparticles can be conducted for efficient local delivery of the drug into the posterior segment
of the eye, hence a sustained release formulation may be of great importance that reduces the
frequent administration of intravitreal injection. Thus, this is an attractive approach that can be
further investigated in vivo and in clinical setting to demonstrate its application for wet AMD
therapy.
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